Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.37 and traded as high as $1.76. Cortexyme shares last traded at $1.69, with a volume of 166,060 shares traded.
Cortexyme Stock Up 0.6%
The firm has a market cap of $50.96 million, a P/E ratio of -0.57 and a beta of 1.40. The firm’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.37.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- How to Short Nasdaq: An Easy-to-Follow Guide
- Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
- How to Profit From Growth Investing
- Why Datadog Is the AI Infrastructure Firm to Watch Out For
- What is a penny stock? A comprehensive guide
- 4 Stocks Every AI ETF Is Buying—And They’re Not What You Think
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
